Skip to main content

Table 1 Demographic and clinical characteristics of patients with poorly controlled T2DM at baseline, stratified by SNCP and UNC

From: Effectiveness of standardized nursing care plans to achieve A1C, blood pressure, and LDL-C goals among people with poorly controlled type 2 diabetes mellitus at baseline: four-year follow-up study

 

A1C ≥7% (n = 1916)

DBP ≥80 mmHg (n = 1170)

SBP ≥ 130 mmHg (n = 2471)

LDL Chol ≥100 mg/dl (n = 2473)

SNCP (n = 1035)

UNC (n = 881)

p value

SNCP (n = 552)

UNC (n = 618)

p value

SNCP (n = 1267)

UNC (n = 1204)

p value

SNCP (n = 1216)

UNC (n = 1257)

p value

Gender female n (%)

581 (56.2)

473 (53.7)

0.27

299 (54.2)

337 (54.5)

0.90

741 (58.5)

677 (56.2)

0.25

684 (56.3)

711 (56.6)

0.89

Age mean (sd)

70 (10)

67.7 (11)

0.00

67.5 (10)

66.3 (10)

0.05

71.5 (8.7)

70.2 (9.3)

0.00

70 (10)

67.9 (10.2)

0.00

Tobacco n (%)

205 (19.8)

190 (21.6)

0.34

120 (21.7)

122 (19.7)

0.40

221 (17.4)

208 (17.3)

0.91

218 (17.9)

238 (18.9)

0.52

CAD n (%)

159 (15.4)

115 (13.1)

0.15

39 (7.1)

49 (7.9)

0.58

151 (11.9)

123 (10.2)

0.18

103 (8.5)

102 (8.1)

0.75

Dyslpidemia n (%)

571 (55.2)

451 (51.2)

0.08

293 (53.1)

323 (52.3)

0.78

684 (54)

616 (51.2)

0.16

682 (56.1)

658 (52.3)

0.06

Retinopathy n (%)

60 (5.8)

53 (6)

0.84

20 (3.6)

16 (2.6)

0.31

60 (4.7)

43 (3.6)

0.15

57 (4.7)

38 (3)

0.03

Nephropathy n (%)

58 (5.6)

47 (5.3)

0.80

28 (5.1)

31 (5)

0.97

78 (6.2)

68 (5.6)

0.59

57 (4.7)

65 (5.2)

0.58

Neuropathy n (%)

21 (2)

24 (2.7)

0.32

7 (1.3)

8 (1.3)

0.97

19 (1.5)

21 (1.7)

0.63

19 (1.6)

19 (1.5)

0.92

Hypertension n (%)

705 (68.1)

624 (70.8)

0.20

429 (77.7)

510 (82.5)

0.04

997 (78.7)

975 (81)

0.16

838 (68.9)

871 (69.3)

0.84

OAD n (%)

885 (85.5)

743 (84.3)

0.48

430 (77.9)

452 (73.1)

0.06

1008 (80)

902 (74.9)

0.00

924 (76)

884 (70.3)

0.00

Insulin n (%)

344 (33.2)

282 (32)

0.57

104 (18.8)

73 (11.8)

0.00

279 (22)

207 (17.2)

0.00

208 (17.1)

187 (14.9)

0.13

OAD + Insulin n (%)

233 (22.5)

184 (20.9)

0.39

76 (13.8)

49 (7.9)

0.00

201 (15.9)

140 (11.6)

0.00

142 (11.7)

122 (9.7)

0.11

Statins n (%)

665 (64.3)

529 (60)

0.06

306 (55.4)

348 (56.3)

0.76

774 (61.1)

712 (59.1)

0.32

681 (56)

707 (56.2)

0.90

Diuretics n (%)

249 (24.1)

249 (28.3)

0.04

146 (26.4)

186 (30.1)

0.17

361 (28.5)

370 (30.7)

0.22

299 (24.6)

337 (26.8)

0.21

Beta-blocker n (%)

159 (15.4)

158 (17.9)

0.13

87 (15.8)

121 (19.6)

0.09

195 (15.4)

214 (17.8)

0.11

165 (13.6)

201 (16)

0.09

Calcium channel blocker n (%)

243 (23.5)

195 (22.1)

0.49

118 (21.4)

143 (23.1)

0.47

326 (25.7)

291 (24.2)

0.37

244 (20.1)

249 (19.8)

0.87

ACE n (%)

407 (39.3)

378 (42.9)

0.11

245 (44.4)

281 (45.5)

0.71

559 (44.1)

561 (46.6)

0.22

461 (37.9)

484 (38.5)

0.76

ARB n (%)

288 (27.8)

231 (26.2)

0.43

169 (30.6)

178 (28.8)

0.50

398 (31.4)

347 (28.8)

0.16

307 (25.2)

283 (22.5)

0.11

Antiplatelet n (%)

742 (71.7)

612 (69.5)

0.29

358 (64.9)

401 (64.9)

0.99

891 (70.3)

827 (68.7)

0.38

796 (65.5)

808 (64.3)

0.54

  1. CAD Coronary arterie disease, OAD Oral antidiabetes drug, ACE Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blocker